MedTrace Logo

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

NCT05572801 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-08-14

No results posted yet for this study

Summary

This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.

Conditions

Interventions

DIAGNOSTIC_TEST

AMR B: HPV positive ctDNA guided imaging in follow-up

Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure

Sponsors & Collaborators

  • Danish Comprehensive Cancer Center

    collaborator OTHER

  • Nordic Cancer Union

    collaborator OTHER

  • The regions medicine- and treatment funds

    collaborator UNKNOWN

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Karen-Lise G Spindler, Professor · Department of Experimental Clinical Oncology Aarhus Univeristy Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2026-06-01
Completion
2031-06-01

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572801 on ClinicalTrials.gov